[{"id":"c6f9cbc2-76fa-4211-9fb0-5b14aa0568d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04020575","created_at":"2021-01-18T19:44:34.590Z","updated_at":"2024-07-02T16:35:45.435Z","phase":"Phase 1","brief_title":"Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)","source_id_and_acronym":"NCT04020575","lead_sponsor":"Minerva Biotechnologies Corporation","biomarkers":" HER-2 • PGR • MUC1","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR negative • ER negative • MUC1 expression • HR positive + HER-2 negative","tags":["HER-2 • PGR • MUC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR negative • ER negative • MUC1 expression • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e huMNC2-CAR22 • huMNC2-CAR44 CAR T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 69","initiation":"Initiation: 01/15/2020","start_date":" 01/15/2020","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/15/2035","study_completion_date":" 01/15/2035","last_update_posted":"2023-06-16"}]